Undermining PDL1/2 signaling and consequently overcoming this immune evasion has become the focus of PD1/PDL1 driven immune checkpoint inhibition studies, as was successfully shown in initial clinical trials for relapsed or refractory HL [25]. Here, CD274 is linked to Hodgkins lymphoma.